US Stock MarketDetailed Quotes

NAMS NewAmsterdam Pharma

Watchlist
  • 23.370
  • -0.210-0.89%
Close Mar 14 16:00 ET
  • 23.370
  • 0.0000.00%
Post 16:05 ET
2.57BMarket Cap-9.13P/E (TTM)

About NewAmsterdam Pharma Company

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Company Profile

SymbolNAMS
Company NameNewAmsterdam Pharma
Listing DateFeb 8, 2021
Founded2022
CEODr. Michael Harvey Davidson, M.D.
MarketNASDAQ
Employees68
Fiscal Year Ends12-31
AddressGooimeer 2-35
CityNaarden
ProvinceNoord-Holland
CountryNetherlands (the)
Zip Code1411 DC
Phone31-35-206-29-71

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Michael Harvey Davidson, M.D.
  • Chief Executive Officer and Director
  • 6.47M
  • Douglas F. Kling
  • Chief Operating Officer
  • 2.58M
  • Ian Somaiya
  • Chief Financial Officer
  • 1.25M
  • Louise Kooij
  • Chief Accounting Officer
  • --
  • William B.J. Jones, Jr
  • Chief Commercial Officer
  • --
  • Dr. Johannes Jacob Pieter Kastelein, M.D.
  • Chief Scientific Officer and Director
  • 3.38M
  • Juliette Audet
  • Chief Business Officer
  • 10.00K
  • William H. Lewis, J.D.,M.B.A.
  • Chairman of the Board
  • --
  • Janneke van der Kamp
  • Independent Director
  • 97.79K
  • Wouter Joustra
  • Independent Director
  • 20.00K
  • John W. Smither
  • Independent Director
  • 108.92K
  • Louis G. Lange, M.D.
  • Independent Director
  • 109.17K
  • Dr. James N. Topper, M.D.,PhD
  • Independent Director
  • 40.00K
  • Dr. Nicholas S. Downing, M.D.
  • Independent Director
  • 44.00K
  • Mark C. McKenna
  • Independent Director
  • 687.50K

Trending Stocks

Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More